Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for Prostate and Liver Cancer.
DNA compaction
chemotherapy
doxorubicin
gemini surfactants
gold nanoparticles
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Dec 2022
08 Dec 2022
Historique:
received:
21
10
2022
revised:
02
12
2022
accepted:
05
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Different gold nanosystems covered with DNA and doxorubicin (Doxo) were designed and synthesized for cancer therapy, starting from Au@16-Ph-16 cationic nanoparticles and DNA-Doxo complexes prepared under saturation conditions. For the preparation of stable, biocompatible, and small-sized compacted Au@16-Ph-16/DNA-Doxo nanotransporters, the conditions for the DNA-Doxo compaction process induced by gold nanoparticles were first explored using fluorescence spectroscopy, circular dichroism and atomic force microscopy techniques. The reverse process, which is fundamental for Doxo liberation at the site of action, was found to occur at higher C
Identifiants
pubmed: 36555216
pii: ijms232415575
doi: 10.3390/ijms232415575
pmc: PMC9779246
pii:
doi:
Substances chimiques
Gold
7440-57-5
doxorubicin-DNA
0
Doxorubicin
80168379AG
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Seville, Spain VI PP Use of General Research Services
ID : PPI534/2020, PPI539/2020 and 2021/0000129
Organisme : Andalusian Research, Development and Innovation Plan
ID : (PAIDI) 2020 a 2021/FQM-386
Organisme : Spanish Ministry of Science, Innovation and Universities
ID : (PID2019-105564RB-I00; FPU18/02485)
Organisme : CIBERobn
ID : (CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain)
Références
Prog Mol Biol Transl Sci. 2011;104:299-323
pubmed: 22093222
Phys Chem Chem Phys. 2018 Oct 3;20(38):24902-24914
pubmed: 30234871
Adv Biomed Res. 2012;1:27
pubmed: 23210086
J Colloid Interface Sci. 2008 Jul 1;323(1):75-83
pubmed: 18440012
ACS Nano. 2014 Jul 22;8(7):6633-43
pubmed: 24963790
Phys Chem Chem Phys. 2013 Dec 14;15(46):20064-74
pubmed: 24153408
J Nucl Med. 2000 Apr;41(4):622-30
pubmed: 10768562
Pharmaceutics. 2021 Apr 20;13(4):
pubmed: 33924284
J Phys Chem B. 2014 Feb 6;118(5):1288-95
pubmed: 24417409
Artif Cells Nanomed Biotechnol. 2015;43(5):311-7
pubmed: 24588231
FASEB J. 2017 Nov;31(11):4682-4696
pubmed: 28705809
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Biomaterials. 2008 Sep;29(26):3583-90
pubmed: 18533252
J Drug Target. 2020 Jun;28(5):468-486
pubmed: 31984810
Biophys Chem. 1998 Jul 27;73(3):249-63
pubmed: 9700924
Curr Med Chem. 2009;16(25):3267-85
pubmed: 19548866
Polymers (Basel). 2018 Dec 03;10(12):
pubmed: 30961261
Pharmacol Ther. 1990;47(2):219-31
pubmed: 2203071
ACS Nano. 2014 May 27;8(5):5132-40
pubmed: 24694301
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Ann Oncol. 2004 Jun;15(6):891-5
pubmed: 15151945
Pharmaceutics. 2021 Mar 21;13(3):
pubmed: 33801142
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Oncol Pharm Pract. 2007 Jun;13(2):105-7
pubmed: 17873110
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Ann Oncol. 2005 Feb;16(2):300-6
pubmed: 15668288
J Clin Oncol. 2002 Feb 15;20(4):1087-93
pubmed: 11844834
Expert Opin Pharmacother. 2002 Dec;3(12):1739-51
pubmed: 12472371
Arch Dermatol. 2000 Dec;136(12):1475-80
pubmed: 11115157
J Phys Condens Matter. 2017 May 24;29(20):203002
pubmed: 28426435
Int J Nanomedicine. 2014 May 06;9 Suppl 1:51-63
pubmed: 24872703
Clin Cancer Res. 2002 Feb;8(2):413-8
pubmed: 11839657
Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2656-63
pubmed: 25257405
ACS Nano. 2011 Nov 22;5(11):8783-9
pubmed: 21988181
Mol Cancer Res. 2017 Jul;15(7):862-874
pubmed: 28385910
Cell Death Dis. 2020 May 29;11(5):406
pubmed: 32471991
J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8
pubmed: 25579518
Eur J Biochem. 1992 Mar 15;204(3):1035-9
pubmed: 1551384
Biomed Res Int. 2014;2014:498420
pubmed: 25165707
Adv Drug Deliv Rev. 2011 May 30;63(6):456-69
pubmed: 21315781
Chempluschem. 2020 Sep;85(9):2143-2157
pubmed: 32864902
PLoS One. 2011;6(5):e20271
pubmed: 21633508
Prostate. 2001 Aug 1;48(3):188-99
pubmed: 11494334
J Control Release. 2010 Dec 1;148(2):135-46
pubmed: 20797419
Jpn J Clin Oncol. 2008 Nov;38(11):777-85
pubmed: 18927230
Phys Chem Chem Phys. 2011 Jan 28;13(4):1479-89
pubmed: 21132199
Cancers (Basel). 2020 Mar 09;12(3):
pubmed: 32182954
J Am Chem Soc. 2012 Aug 15;134(32):13396-403
pubmed: 22803823
Cancer Lett. 2021 Jan 1;496:72-83
pubmed: 33038489
PLoS One. 2010 Oct 11;5(10):e13308
pubmed: 20949017
Biochim Biophys Acta. 2002 Dec 23;1567(1-2):150-6
pubmed: 12488048
Rev Sci Instrum. 2007 Jan;78(1):013705
pubmed: 17503926
Onkologie. 2011;34(4):184-8
pubmed: 21447976
Small. 2014 Nov;10(22):4626-35
pubmed: 24955859
Int J Nanomedicine. 2017 Dec 22;13:143-159
pubmed: 29317822
Nanotechnology. 2019 Aug 2;30(31):315101
pubmed: 30991371
Am J Cancer Res. 2017 Mar 01;7(3):715-726
pubmed: 28401023
J Acquir Immune Defic Syndr (1988). 1994 May;7(5):463-8
pubmed: 8158540
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
Int J Clin Oncol. 2013 Oct;18(5):927-33
pubmed: 22911020
J Med Life. 2017 Jan-Mar;10(1):5-12
pubmed: 28255369
ACS Nano. 2012 Oct 23;6(10):8684-91
pubmed: 22950811
Int J Cardiol. 2012 Apr 5;156(1):4-10
pubmed: 21636148
J Mater Chem B. 2014 Aug 14;2(30):4901-4910
pubmed: 32261782
Mol Ther. 2003 Oct;8(4):646-53
pubmed: 14529838
Theranostics. 2016 Mar 20;6(5):710-25
pubmed: 27022418
Int J Mol Sci. 2021 May 19;22(10):
pubmed: 34069373
PLoS One. 2015 Mar 05;10(3):e0119214
pubmed: 25742619
J Biochem. 1980 Mar;87(3):911-8
pubmed: 7390968
Cytogenet Cell Genet. 1999;87(3-4):225-32
pubmed: 10702678
Curr Top Med Chem. 2014;14(6):766-73
pubmed: 24444152
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):187-203
pubmed: 11259840
Expert Opin Drug Deliv. 2022 Jun;19(6):707-723
pubmed: 35618266
J Mol Biol. 1965 Sep;13(2):407-27
pubmed: 5867028
Ann Oncol. 2010 Nov;21(11):2227-2232
pubmed: 20439345
J Pharm Pharmacol. 2016 Jun;68(6):729-41
pubmed: 26989862
Br J Cancer. 2001 Apr 20;84(8):1029-35
pubmed: 11308249
Mol Pharm. 2013 Jun 3;10(6):2093-110
pubmed: 23461379
Br J Cancer. 2006 Oct 9;95(7):822-8
pubmed: 16969346
Nucleic Acids Res. 2012 Jan;40(1):284-9
pubmed: 21896618
EBioMedicine. 2020 Jan;51:102547
pubmed: 31902674
Curr Drug Deliv. 2005 Oct;2(4):443-9
pubmed: 16305447
Int J Biochem Cell Biol. 2006;38(10):1766-77
pubmed: 16798056
Eur J Pharm Biopharm. 2017 Oct;119:372-380
pubmed: 28736333
Langmuir. 2012 Jul 31;28(30):10968-79
pubmed: 22755509
Int J Nanomedicine. 2020 Dec 17;15:10285-10304
pubmed: 33376322
Adv Mater. 2013 Aug 27;25(32):4386-96
pubmed: 23765613
Commun Biol. 2020 Apr 30;3(1):205
pubmed: 32355216
Nat Protoc. 2007;2(12):3166-72
pubmed: 18079716
J Cancer Res Clin Oncol. 2021 Jan;147(1):167-175
pubmed: 32980960